http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02078634-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d548d5152df022c3485c5f3a742490a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8873370afd07bce8a3e2bb94910147de |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-665 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-665 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 |
| filingDate | 2002-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9be7cce04e2b076ed363c9272cbcf517 |
| publicationDate | 2003-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-02078634-A3 |
| titleOfInvention | Methods for using kdop and kdop synthase inhibitors for the treatment of bacterial infection |
| abstract | The two crystal structures of KDOPS that we present here illustrate the value of protein crystal structural analysis for characterizing the enzymatic reaction mechanism of KDOPS. Mechanistic hypotheses have underscored certain specifics of the interaction between the enzyme and the substrate, and these features in turn have provided further clarification of the details of the enzymatic reaction. The structure and function of 3-deoxy-D-manno-2-octulosonate-8-phosphate (KDOSP) synthase, discussed herein provide a new target antibacterial drugs. KDO8P synthase catalyzes the synthesis of a unique sugar that is a required component of the outer membrane lipopolysaccharides of Gram-negative bacteria. The enzyme activity is required for the full viability of Gram-negative bacteria. Overall these disclosures provide a new method for developing new drugs, and methods of using the same to treat infections caused by bacteria that are resistant to conventional drugs. |
| priorityDate | 2001-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.